Crit Care 2006,10(4):R120.PubMedCrossRef 17. Meng ZH, Wolberg AS, Monroe DM 3rd, et al.: The selleck products effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003,55(5):886–91.PubMedCrossRef 18. Lesperance RN, Lehmann RK, Harold DM, et al.: Recombinant Factor VII is Effective at Reversing Coagulopathy in a Lactic Acidosis Model. J Trauma 2011. [Epub ahead of print] 19. Ho KM, Litton E: Cost-effectiveness of using recombinant activated factor Mizoribine VII as an off-label rescue treatment for critical bleeding requiring massive transfusion. Transfusion 2011. doi: 10.1111/j.1537–2995.2011.03505.x. [Epub
ahead of print] 20. Selleckchem NVP-BEZ235 Nascimento B, Lin Y, Callum J, et al.: Recombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients. Clinics (Sao Paulo) 2011,66(1):101–6.CrossRef 21. Rizoli SB, Nascimento B Jr, Osman F, et al.: Recombinant activated
coagulation factor VII and bleeding trauma patients. J Trauma 2006,61(6):1419–25.PubMedCrossRef 22. David : Recombinant Activated Human Factor VII (NovoSeven). [http://www.canadianmedicine4all.com/recombinant-activated-human-factor-vii-novoseven.html] 23. Stein DM, Dutton RP, Hess JR, et al.: Low-dose recombinant factor VIIa for trauma patients with coagulopathy. Injury 2008,39(9):1054–61.PubMedCrossRef 24. Karkouti K, Beattie
WS, Arellano R, et al.: Comprehensive Canadian Review of the Off-Label Use of Recombinant Activated Factor VII in Cardiac Surgery. Circulation 2008,118(4):331–8. Epub 2008 Jul 7PubMedCrossRef 25. James I, John M: Australia and New Zealand Haemostasis Registry. Monsah University, Australia; 2010. 26. Hess JR, Brohi K, Dutton RP, et al.: The Coagulopathy of Trauma: A Review of Mechanisms. J Trauma 2008,65(4):748–54. ReviewPubMedCrossRef 27. Knudson MM, Cohen MJ, Reidy R, et al.: Trauma, Transfusions, and Use of Recombinant Factor VIIa: A Multicenter Case Registry Report of 380 patients from the Western Trauma Association. Bay 11-7085 J Am Coll Surg 2011,212(1):87–95. Epub 2010 Nov 5PubMedCrossRef 28. CRASH-2 Trial Collaborators: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) a randomized, placebo-controlled trial. Lancet 2010,376(9734):23–32. Epub 2010 Jun 14CrossRef 29. Guerriero C, Cairns J, Perel P, et al.: Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS One 2011,6(5):e18987.PubMedCrossRef 30. Charoencholvanich K, Siriwattanasakul P: Tranexamic Acid Reduces Blood Loss and Blood Transfusion after TKA: A Prospective Randomized Controlled Trial. Clin Orthop Relat Res 2011. Epub ahead of print 31.